These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Intrathecal ziconotide for complex regional pain syndrome: seven case reports. Kapural L; Lokey K; Leong MS; Fiekowsky S; Stanton-Hicks M; Sapienza-Crawford AJ; Webster LR Pain Pract; 2009; 9(4):296-303. PubMed ID: 19500276 [TBL] [Abstract][Full Text] [Related]
23. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Jain KK Expert Opin Investig Drugs; 2000 Oct; 9(10):2403-10. PubMed ID: 11060815 [TBL] [Abstract][Full Text] [Related]
24. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Wallace MS Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783 [TBL] [Abstract][Full Text] [Related]
25. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability. Pope JE; Deer TR Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382 [TBL] [Abstract][Full Text] [Related]
27. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Wermeling DP; Berger JR Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720 [TBL] [Abstract][Full Text] [Related]
29. Ziconotide: an update and review. Williams JA; Day M; Heavner JE Expert Opin Pharmacother; 2008 Jun; 9(9):1575-83. PubMed ID: 18518786 [TBL] [Abstract][Full Text] [Related]
30. Intrathecal ziconotide for neuropathic pain: a review. Rauck RL; Wallace MS; Burton AW; Kapural L; North JM Pain Pract; 2009; 9(5):327-37. PubMed ID: 19682321 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352 [TBL] [Abstract][Full Text] [Related]
32. Ziconotide Combination Intrathecal Therapy for Noncancer Pain Is Limited Secondary to Delayed Adverse Effects: A Case Series With a 24-Month Follow-Up. Hayek SM; Hanes MC; Wang C; Veizi IE Neuromodulation; 2015 Jul; 18(5):397-403. PubMed ID: 25655991 [TBL] [Abstract][Full Text] [Related]
33. Considerations and methodology for trialing ziconotide. Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460 [TBL] [Abstract][Full Text] [Related]
34. The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature. Webster LR Pain Med; 2015 Jul; 16(7):1265-77. PubMed ID: 25645109 [TBL] [Abstract][Full Text] [Related]
35. Ziconotide: a clinical update and pharmacologic review. Pope JE; Deer TR Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340 [TBL] [Abstract][Full Text] [Related]
36. Ziconotide for treatment of severe chronic pain. Schmidtko A; Lötsch J; Freynhagen R; Geisslinger G Lancet; 2010 May; 375(9725):1569-77. PubMed ID: 20413151 [TBL] [Abstract][Full Text] [Related]
37. Adverse effects associated with the intrathecal administration of ziconotide. Penn RD; Paice JA Pain; 2000 Mar; 85(1-2):291-6. PubMed ID: 10692631 [TBL] [Abstract][Full Text] [Related]